跳至主要内容
临床试验/NCT02102997
NCT02102997
终止
不适用

Deutsches Dual Therapy Stent Register

OrbusNeich1 个研究点 分布在 1 个国家目标入组 130 人2013年7月

概览

阶段
不适用
干预措施
未指定
疾病 / 适应症
Coronary Artery Disease
发起方
OrbusNeich
入组人数
130
试验地点
1
主要终点
Target Vessel Failure (TVF)
状态
终止
最后更新
8年前

概览

简要总结

The DTS.DE registry is an initiative for the collection of high quality process and historical data of implantations with the COMBO Dual Therapy Stent in Germany. DTS.DE was designed as a national, non- randomized, prospective, multicenter registry without a comparison group.

The responsible Steering Committee is of the opinion that the Combo stent qualifies for further documentation of treatment results in the form of a German registry, based the CE certification of the COMBO Dual Therapy stent in 2013 and its clinical and scientific investigation in the context of the REMEDEE study program, as well as company independent externally initiated studies with the COMBO Dual Therapy Stent.

It is expected that by mid- 2015, at least 1,000 patients will be enrolled and documented in the DTS.DE registry with the COMBO Dual Therapy Stent. A clinical follow-up is performed after 6 weeks and 12 months.

详细描述

It is the objective of the DTS.DE registry to capture the documentation of all patients who have been treated with a Combo Dual Therapy Stent in Germany, and who have been properly informed and consented with regards to their participation in the registry. All of these patients will be registered in the electronic data capturing system (eCRF) of the DTS.DE registry and will be followed and documented for a period of 12 months.

注册库
clinicaltrials.gov
开始日期
2013年7月
结束日期
2017年11月
最后更新
8年前
研究类型
Observational
性别
All

研究者

发起方
OrbusNeich
责任方
Sponsor

入排标准

入选标准

  • Patients has at least one coronary lesion, suitable for PCI treatment with the Combo stent in accordance with European Society of Cardiology Guidelines and local Guidelines of the Deutsche Gesellschaft für Kardiologie for drug eluting stents

排除标准

  • Patient has previously received murine therapeutic antibodies and exhibited sensitization through the production of Human Anti- Murine Antibodies (HAMA)
  • Patient in whom anti-platelet and/or anticoagulant therapy is contraindicated
  • Patient in whom a complete inflation of the angioplasty balloon or correct stent placement is thought to be inhibited

结局指标

主要结局

Target Vessel Failure (TVF)

时间窗: 12 months

TVF is defined as the hierarchical composite of target vessel related Major Adverse Cardiac Events (MACE). MACE is defined as the composite of death, myocardial infarction and target lesion revascularization (TLR).

次要结局

  • Stent thrombosis(12 months)
  • Thrombolysis in Myocardial Infarction (TIMI) bleeding(12 months)
  • Stent induced serious adverse events (SAE)(12 months)
  • Procedural success(Day of procedure)
  • MACE(6 weeks and 12 months)

研究点 (1)

Loading locations...

相似试验